![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Option Care Health has been selected to participate in the limited distribution network of VILTEPSO™ (viltolarsen) for patients with Duchenne Muscular Dystrophy (“DMD”) who are amenable to exon 53 skipping therapy.
Lead Product(s): Viltolarsen
Therapeutic Area: Genetic Disease Product Name: Viltepso
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: NS Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 02, 2020